Latest news with #TransMedicsGroup
Yahoo
21-05-2025
- Business
- Yahoo
Assessing TransMedics Group And Two Other Stocks That Might Be Trading Below Estimated Value
As the U.S. market navigates a landscape marked by fluctuating indices and rising Treasury yields, investors are closely watching legislative developments that could impact economic conditions. Amidst this environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for those looking to capitalize on market inefficiencies. Name Current Price Fair Value (Est) Discount (Est) Berkshire Hills Bancorp (NYSE:BHLB) $26.27 $51.54 49% Quaker Chemical (NYSE:KWR) $107.26 $210.06 48.9% Super Group (SGHC) (NYSE:SGHC) $8.44 $16.54 49% KBR (NYSE:KBR) $55.33 $108.40 49% Horizon Bancorp (NasdaqGS:HBNC) $15.69 $30.68 48.9% Insteel Industries (NYSE:IIIN) $36.65 $72.23 49.3% First Reliance Bancshares (OTCPK:FSRL) $9.45 $18.49 48.9% Carvana (NYSE:CVNA) $302.29 $586.89 48.5% Verra Mobility (NasdaqCM:VRRM) $24.53 $47.91 48.8% Mobileye Global (NasdaqGS:MBLY) $16.05 $31.07 48.3% Click here to see the full list of 171 stocks from our Undervalued US Stocks Based On Cash Flows screener. Here's a peek at a few of the choices from the screener. Overview: TransMedics Group, Inc. is a commercial-stage medical technology company focused on transforming organ transplant therapy for end-stage organ failure patients globally, with a market cap of $4.13 billion. Operations: The company's revenue is primarily derived from its Surgical & Medical Equipment segment, which generated $488.23 million. Estimated Discount To Fair Value: 47.9% TransMedics Group is trading at US$124.71, significantly below its estimated fair value of US$239.19, suggesting it may be undervalued based on cash flows. Recent earnings showed strong growth with Q1 2025 revenue at US$143.54 million and net income of US$25.68 million, reflecting improved profitability. The company's revised full-year revenue guidance projects up to $585 million, indicating robust future growth potential despite debt concerns not fully covered by operating cash flow. The growth report we've compiled suggests that TransMedics Group's future prospects could be on the up. Click here to discover the nuances of TransMedics Group with our detailed financial health report. Overview: Willdan Group, Inc. offers professional, technical, and consulting services mainly in the United States and has a market cap of $731.80 million. Operations: The company's revenue is derived from two main segments: Energy, contributing $498.81 million, and Engineering & Consulting, accounting for $96.88 million. Estimated Discount To Fair Value: 14.9% Willdan Group, trading at US$50.55, is undervalued based on cash flows with an estimated fair value of US$59.43. Earnings are expected to grow significantly at 23.4% annually, outpacing the broader US market. Recent Q1 2025 results showed a revenue increase to US$152.39 million and net income of US$4.69 million, reflecting ongoing profitability improvements amid strategic acquisitions and expanded credit facilities enhancing financial flexibility for future growth initiatives. Our comprehensive growth report raises the possibility that Willdan Group is poised for substantial financial growth. Dive into the specifics of Willdan Group here with our thorough financial health report. Overview: Grindr Inc. operates a social networking and dating application catering to the LGBTQ community globally, with a market cap of $4.66 billion. Operations: The company's revenue primarily comes from its Internet Information Providers segment, generating $363.23 million. Estimated Discount To Fair Value: 31.4% Grindr, trading at US$24.31, is significantly undervalued with a fair value estimate of US$35.45. The company reported Q1 2025 sales of US$93.94 million and net income of US$27.02 million, reversing a previous loss, alongside raised full-year revenue growth guidance to 26% or more. Despite insider selling and profitability expected within three years, Grindr's strategic expansions and share buyback program underscore its potential for enhanced cash flow valuation. According our earnings growth report, there's an indication that Grindr might be ready to expand. Take a closer look at Grindr's balance sheet health here in our report. Unlock more gems! Our Undervalued US Stocks Based On Cash Flows screener has unearthed 168 more companies for you to here to unveil our expertly curated list of 171 Undervalued US Stocks Based On Cash Flows. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:TMDX NasdaqGM:WLDN and NYSE:GRND. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
TransMedics to Present at Upcoming June Investor Conferences
ANDOVER, Mass., May 20, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to present at the William Blair 45th Annual Growth Stock Conference in Chicago on Tuesday, June 3, 2025, at 5:00 p.m. EST and participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on Monday, June 9, 2025, at 8:00 a.m. EST. Event: William Blair 45th Annual Growth Stock ConferenceDate: Tuesday, June 3, 2025Time: 5:00 p.m. EST Event: Goldman Sachs 46th Annual Global Healthcare ConferenceDate: Monday, June 9, 2025Time: 8:00 a.m. EST A live and archived webcast of the presentations will be available on the "Investors" section of the TransMedics website at The Company's standard investor presentation is also available through this link. About TransMedics Group, is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Investor Contact:Brian JohnstonLaine Morgan332-895-3222Investors@ View original content to download multimedia: SOURCE TransMedics Group, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
2 Brilliant Stocks to Buy With $200 and Hold for 5 Years
TansMedics Group is helping improve patient outcomes in the organ transplant field. Exact Sciences has helped increase colorectal cancer detection. 10 stocks we like better than TransMedics Group › While being an innovative company doesn't guarantee superior long-term returns, it doesn't hurt those chances either. In fact, when a corporation is making important breakthroughs and boasts significant growth prospects in its industry, that could translate to above-average stock market performances over five years or more. That description fits TransMedics Group (NASDAQ: TMDX) and Exact Sciences (NASDAQ: EXAS), two innovative healthcare leaders. Here's why these companies could deliver strong returns through the end of the decade. TransMedics Group developed a revolutionary way to store organs before transplants. The company's Organ Care System (OCS) mimics the physiology of the human body, resulting in a higher usage rate for the organs it is approved for -- lungs, hearts, and kidneys -- than the traditional cold storage method. In a clinical trial, 32% of hearts kept in cold storage were used in a transplant, versus 81% for the OCS. The company's technology is superior; that's why it has gained traction. TransMedics Group has encountered some issues recently. The company's revenue growth slowed, while its guidance disappointed investors. Further, the medical device specialist became the target of serious allegations from an activist short-seller. However, TransMedics Group is rebounding, partly thanks to recent stronger-than-expected first-quarter results. TransMedics Group's stock jumped by about 20% on the heels of its most recent quarterly update. Still, the company's shares remain down by 11% in the past year, and there could be significant upside potential for the company in the next five years. TransMedics Group estimates that deceased donations of organs will continue to increase in the next few years. Meanwhile, there are more people in need of organs than the number of those willing to donate theirs. For the ones available, keeping them in the best possible shape for transplants is incredibly important. TransMedics Group's OCS is one of the better options on the market for doing just that. So, the company should continue growing its revenue and earnings at a good clip in the next five years, and likely beyond that. And in the meantime, the company could deliver excellent returns to investors. Investors can buy one of TransMedics Group's shares at current levels with $200. Exact Sciences is a healthcare company that develops cancer diagnostic tests. The company is best known for Cologuard, a non-invasive, at-home test for colorectal cancer (CRC) -- the second leading cause of cancer death worldwide. The fact that the disease is highly treatable when caught early, and yet kills as many patients as it does, suggests that not enough eligible people are getting screened. For those at average risk of CRC, it is recommended to start screening at 45 years old. Exact Sciences has made significant headway in this market. It first earned clearance for Cologuard in the U.S. in 2014; by 2022, it had been used to screen 10 million patients. Exact Sciences has encountered some headwinds in the past few years, including slower revenue growth and persistent net losses. However, recent developments could help the company fix this issue. In October, it earned approval for the next-gen version of its crown jewel, Cologuard Plus. This newer test proved superior at identifying true positives and false negatives, and should, therefore, help attract even more prescriptions from otherwise skeptical physicians. The new Cologuard is also 5% cheaper to manufacture. That should make a meaningful difference in the company's costs across millions of tests. Further, Exact Sciences recently launched Oncodetect, which is designed to check for cancer recurrence in patients across several solid tumors. Lastly, Exact Sciences plans to debut another product later this year, a multicancer-detecting test called Cancerguard. With these new products and the company's well-established Cologuard franchise, expect stronger revenue growth and, eventually, net profits before the end of the decade. The stock could deliver superior returns. Exact Sciences' shares are trading hands for just under $54, so $200 is good for three. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $598,613!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $753,878!* Now, it's worth noting Stock Advisor's total average return is 922% — a market-crushing outperformance compared to 169% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 12, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends TransMedics Group. The Motley Fool recommends Exact Sciences. The Motley Fool has a disclosure policy. 2 Brilliant Stocks to Buy With $200 and Hold for 5 Years was originally published by The Motley Fool
Yahoo
13-05-2025
- Business
- Yahoo
Is TransMedics Group, Inc. (TMDX) the Unstoppable Growth Stock to Invest in Now?
We recently published a list of . In this article, we are going to take a look at where TransMedics Group, Inc. (NASDAQ:TMDX) stands against other unstoppable growth stocks to invest in now. BlackRock highlighted that the trade conflict between the US and China continues to cause major economic disruptions. However, the expectations of a supply-driven contraction in the US are very different from a typical business cycle recession. The hard economic rules binding on policy are expected to limit the damage. Furthermore, the AI mega force has been keeping the firm overweight on the US stocks and positive on developed market stocks, despite the expectations of volatility. BlackRock believes that some of the sectors are more exposed to tariffs as compared to others, with sectoral differences already at play in the earnings releases for Q1 2025. The companies that are at the forefront of the AI mega force continued to keep fueling the US equity strength, while policy uncertainty significantly impacts the broader market. The leading technology companies managed to exceed the Q1 earnings expectations, highlighted the increasing AI-driven demand, and announced plans to raise investments focused on AI. Such trends strengthen the fact that how AI mega force continues to persist despite the supply-driven disruptions. As a result, BlackRock has remained positive on developed market (DM) stocks, primarily the US. On the other hand, automakers have been tagged by the firm as the ones most exposed to key supply inputs from China. Furthermore, some of the automakers have highlighted the impact of tariffs in their respective expectations for full-year earnings. READ ALSO: and . Franklin Templeton believes that it is of utmost importance to remember that tough economic and/or market phases are finite. Investors who tend to see most of the profits during the recovery are the ones staying the course during the stormy weather. The investment firm continues to see increased potential for a sustained period of small-cap leadership. Considering its metric of choice to gauge index valuations, EV/EBIT, the Russell 2000 is far more attractively valued as compared to the Russell 1000, says Franklin Templeton. As per the investment manager, the valuation situation becomes even more attractive when consensus earnings growth is included. Notably, growth stocks are the ones capable of increasing their earnings faster as compared to an average business in the respective industry or broader market. At 2024 end, the Russell 2000 was expected to see stronger earnings growth in 2025 as compared to the Russell 1000, based on EPS, added the investment firm. To list the 11 Unstoppable Growth Stocks to Invest in Now, we used a screener to shortlist the companies catering to the growth sectors that have 3-year revenue growth of at least ~25%, and that have appreciated significantly on a YTD basis. We also mentioned hedge fund sentiments around each stock, as of Q4 2024. Finally, the stocks were arranged in ascending order of their hedge fund sentiment. Note: The data was recorded on May 9. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A surgeon in a modern operating theatre performing a transplant surgery with medical Group, Inc. (NASDAQ:TMDX) is a commercial-stage medical technology company that is engaged in transforming organ transplant therapy for end-stage organ failure patients throughout multiple disease states. William Blair analyst, Ryan Daniels, reiterated the bullish stance on the company's stock, giving a 'Buy' rating on May 6. The analyst's rating is backed by a combination of factors demonstrating TransMedics Group, Inc. (NASDAQ:TMDX)'s healthy financial performance and promising growth prospects. As per the analyst, the company reported impressive Q1 2025 results, with sales significantly exceeding expectations and a notable increase in EPS. The financial strength is further bolstered by the management's decision to increase guidance for 2025, reflecting confidence in sustained growth, added Daniels. TransMedics Group, Inc. (NASDAQ:TMDX) posted total revenue of $143.5 million in Q1 2025, reflecting a 48% rise as compared to Q1 2024. Furthermore, the analyst has highlighted the competitive advantages of TransMedics Group, Inc. (NASDAQ:TMDX)'s NOP platform, which provides clinical and operational benefits that can help maintain its market position amidst emerging competition. The company's capability to reap the benefits from new opportunities, together with potential for higher adoption of its platform over the upcoming years, further cements its footing as a compelling growth story, added Daniels. Renaissance Investment Management, an investment management company, released its Q4 2024 investor letter. Here is what the fund said: 'TransMedics Group, Inc. (NASDAQ:TMDX) detracted the most from performance in the quarter as the organ trans plant solutions company reported third-quarter results that were modestly below expectations. However, the company's proprietary organ preservation system coupled with its logistics solutions should allow significant opportunities for market-share gain for a number of years, and we believe that long-term growth opportunities remain intact. Overall, TMDX ranks 5th on our list of unstoppable growth stocks to invest in now. While we acknowledge the potential of TMDX as an investment, our conviction lies in the belief that some deeply undervalued AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for a deeply undervalued AI stock that is more promising than TMDX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
13-05-2025
- Business
- Yahoo
Is TransMedics Group, Inc. (TMDX) the Unstoppable Growth Stock to Invest in Now?
We recently published a list of . In this article, we are going to take a look at where TransMedics Group, Inc. (NASDAQ:TMDX) stands against other unstoppable growth stocks to invest in now. BlackRock highlighted that the trade conflict between the US and China continues to cause major economic disruptions. However, the expectations of a supply-driven contraction in the US are very different from a typical business cycle recession. The hard economic rules binding on policy are expected to limit the damage. Furthermore, the AI mega force has been keeping the firm overweight on the US stocks and positive on developed market stocks, despite the expectations of volatility. BlackRock believes that some of the sectors are more exposed to tariffs as compared to others, with sectoral differences already at play in the earnings releases for Q1 2025. The companies that are at the forefront of the AI mega force continued to keep fueling the US equity strength, while policy uncertainty significantly impacts the broader market. The leading technology companies managed to exceed the Q1 earnings expectations, highlighted the increasing AI-driven demand, and announced plans to raise investments focused on AI. Such trends strengthen the fact that how AI mega force continues to persist despite the supply-driven disruptions. As a result, BlackRock has remained positive on developed market (DM) stocks, primarily the US. On the other hand, automakers have been tagged by the firm as the ones most exposed to key supply inputs from China. Furthermore, some of the automakers have highlighted the impact of tariffs in their respective expectations for full-year earnings. READ ALSO: and . Franklin Templeton believes that it is of utmost importance to remember that tough economic and/or market phases are finite. Investors who tend to see most of the profits during the recovery are the ones staying the course during the stormy weather. The investment firm continues to see increased potential for a sustained period of small-cap leadership. Considering its metric of choice to gauge index valuations, EV/EBIT, the Russell 2000 is far more attractively valued as compared to the Russell 1000, says Franklin Templeton. As per the investment manager, the valuation situation becomes even more attractive when consensus earnings growth is included. Notably, growth stocks are the ones capable of increasing their earnings faster as compared to an average business in the respective industry or broader market. At 2024 end, the Russell 2000 was expected to see stronger earnings growth in 2025 as compared to the Russell 1000, based on EPS, added the investment firm. To list the 11 Unstoppable Growth Stocks to Invest in Now, we used a screener to shortlist the companies catering to the growth sectors that have 3-year revenue growth of at least ~25%, and that have appreciated significantly on a YTD basis. We also mentioned hedge fund sentiments around each stock, as of Q4 2024. Finally, the stocks were arranged in ascending order of their hedge fund sentiment. Note: The data was recorded on May 9. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A surgeon in a modern operating theatre performing a transplant surgery with medical Group, Inc. (NASDAQ:TMDX) is a commercial-stage medical technology company that is engaged in transforming organ transplant therapy for end-stage organ failure patients throughout multiple disease states. William Blair analyst, Ryan Daniels, reiterated the bullish stance on the company's stock, giving a 'Buy' rating on May 6. The analyst's rating is backed by a combination of factors demonstrating TransMedics Group, Inc. (NASDAQ:TMDX)'s healthy financial performance and promising growth prospects. As per the analyst, the company reported impressive Q1 2025 results, with sales significantly exceeding expectations and a notable increase in EPS. The financial strength is further bolstered by the management's decision to increase guidance for 2025, reflecting confidence in sustained growth, added Daniels. TransMedics Group, Inc. (NASDAQ:TMDX) posted total revenue of $143.5 million in Q1 2025, reflecting a 48% rise as compared to Q1 2024. Furthermore, the analyst has highlighted the competitive advantages of TransMedics Group, Inc. (NASDAQ:TMDX)'s NOP platform, which provides clinical and operational benefits that can help maintain its market position amidst emerging competition. The company's capability to reap the benefits from new opportunities, together with potential for higher adoption of its platform over the upcoming years, further cements its footing as a compelling growth story, added Daniels. Renaissance Investment Management, an investment management company, released its Q4 2024 investor letter. Here is what the fund said: 'TransMedics Group, Inc. (NASDAQ:TMDX) detracted the most from performance in the quarter as the organ trans plant solutions company reported third-quarter results that were modestly below expectations. However, the company's proprietary organ preservation system coupled with its logistics solutions should allow significant opportunities for market-share gain for a number of years, and we believe that long-term growth opportunities remain intact. Overall, TMDX ranks 5th on our list of unstoppable growth stocks to invest in now. While we acknowledge the potential of TMDX as an investment, our conviction lies in the belief that some deeply undervalued AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for a deeply undervalued AI stock that is more promising than TMDX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
